GAROFALO HEALTH CARE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.74 EUR | +0.42% |
|
+0.42% | +2.16% |
| Mar. 14 | GHC, revenues up but profit falls after Aurelia acquisition | AN |
| Mar. 14 | Garofalo Health Care S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in debt and has limited leeway for investment
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.16% | 448M | B | ||
| -20.16% | 16.21B | B+ | ||
| +4.50% | 12.44B | B | ||
| +3.98% | 11.58B | B+ | ||
| +9.72% | 10.79B | B+ | ||
| +23.61% | 8.26B | B | ||
| -2.19% | 7.68B | A- | ||
| +20.75% | 7.2B | D | ||
| +4.49% | 6.67B | B- | ||
| +50.89% | 4.66B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GHC Stock
- Ratings Garofalo Health Care S.p.A.
